Q-omics provides the consensus-scored TCF7 profile across patient tissues and cancer cell-line models. TCF7 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, TCF7 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, TCF7 RNA expression shows 16,402 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight STAD, COAD, and KIRP as cancer lineages where TCF7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TCF7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TCF7 survival associations across molecular data types. TCF7 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TCF7 RNA expression–survival associations across cancer types. High TCF7 expression shows unfavorable associations in LGG and ACC, but favorable associations in STAD, ESCA, BRCA and HNSC. The STAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for TCF7 RNA expression.
This table summarizes TCF7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TCF7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TCF7 shows lower tumor expression in BRCA and higher tumor expression in COAD, STAD, LIHC, KIRC and THCA. The COAD box plot shows higher TCF7 RNA expression in tumor versus normal tissue (log2 FC = +1.974, t-test p < 0.001).
This table shows molecular features associated with TCF7 in patient tissues and cancer cell lines. In patient samples, TCF7 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, TCF7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
